Research on the Biosensing Mechanisms of CRISPR/Cas9 Systems and the Applications in Detection of Non-Infectious Disease
DOI:
https://doi.org/10.61173/mhjwbj88Keywords:
CRISPR/Cas9, Non-Infectious Disease, MechanismAbstract
The CRISPR/Cas9 system has become a groundbreaking technology in molecular diagnostics due to its precise nucleic acid recognition capabilities. This paper comprehensively analyzes the molecular mechanisms of CRISPR-based biosensing platforms, emphasizing target specificity and signal transduction. It reveals how engineered Cas9 variants and optimized guide RNA enhance detection sensitivity, with applications in non-infectious disease monitoring (e.g., early cancer biomarkers). CRISPR-mediated platforms achieve remarkable performance, with detection limits at femtomolar concentrations. The review discusses challenges like off-target effects and signal amplification, proposing solutions involving nanotechnology and microfluidics. Chronic non-communicable conditions challenge global healthcare. CRISPR/Cas9 comprises gRNA and Cas9, with class 2 systems (e.g., Type II) prominent. Cas9 identifies sequences via protospacer adjacent motifs, inducing DNA breaks. Traditional methods are labor-intensive; CRISPR Class 2 platforms enable sensitive, precise detection at lower costs. Emerging Cas variants (e.g., Cpf1) offer enhanced capabilities. Challenges include sample processing and non-specific binding. Future research should simplify protocols and conduct clinical trials. CRISPR/Cas9 advances precision genetic analysis.
References
[1] Alleyne, G., A. Binagwaho, A. Haines, S. et al. Embedding non-communicable diseases in the post-2015 development agenda. 2013. Lancet 381 (9866): 566–574. https://doi. org/10.1016/S0140-6736(12)61806-6.
[2] Jolany Vangah S, Katalani C, Booneh HA, et al. CRISPR- Based Diagnosis of Infectious and Noninfectious Diseases. Biol Proced Online. 2020 Sep 14;22:22.
[3] Wang M, Chen M, Wu X, et al. CRISPR applications in cancer diagnosis and treatment. Cell Mol Biol Lett. 2023 Sep 6;28(1):73.
[4] Shmakov S, Smargon A, Scott D, et al. Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol. 2017;15(3):169–82.
[5] JolanyVangah S, Katalani C, Booneh HA, et al. CRISPR- based diagnosis of infectious and noninfectious diseases. Biol Proced Online. 2020;22:22.
[6] Shmakov S, Abudayyeh OO, Makarova KS, et al. Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell. 2015;60(3):385–97.
[7] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual- RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21.
[8] Hirano S, Nishimasu H, Ishitani R, et al. Structural basis for the altered PAM specifcities of engineered CRISPRCas9. Mol Cell. 2016;61(6):886–94.
[9] Nishimasu H, Ran FA, Hsu PD, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014;156(5):935–49
[10] Hustedt N, Durocher D. The control of DNA repair by the cell cycle. Nat Cell Biol. 2016;19(1):1–9.
[11] Lin S, Staahl BT, Alla RK, et al. Enhanced homologydirected human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. 2014;3: e04766
[12] M. Azangou-Khyavy, M. Ghasemi, J. Khanali, et al. CRISPR/Cas: from tumor gene editing to T cell-based immunotherapy of cancer. Front. Immunol., 11 (2020), p. 2062
[13] J.S. Gootenberg, O.O. Abudayyeh, J.W. Lee, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356 (6336) (2017), pp. 438-442
[14] J.H. Tsou, Q. Leng, F. Jiang. A CRISPR test for rapidly and sensitively detecting circulating EGFR mutations. Diagnostics, 10 (2) (2020), p. 114
[15] F. Liu, J. Peng, Y.M. Lei, et al. Electrochemical detection of ctDNA mutation in non-small cell lung cancer based on CRISPR/Cas12a system. Sensor. Actuator. B Chem., 362 (2022), Article 131807
[16] Hillary, V.E.; Ceasar, S.A. A Review on the mechanism and applications of CRISPR/Cas9/Cas12/Cas13/Cas14 proteins utilized for genome engineering. Mol. Biotechnol. 2023, 65, 311–325.
[17] Wang, Q., Alariqi, M., Wang, F., et al. The application of a heat-inducible CRISPR/Cas12b (C2c1) genome editing system in tetraploid cotton (G. hirsutum) plants. Plant Biotechnol. J. 2020, 18, 2436–2443.
[18] Tian X, Gu T, Patel S, et al. Dong Z.CRISPR-Cas 9–an evolving biological tool kit for cancer biology and oncology. NPJ Precision Oncol. 2019;3(1):1–8.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
